电子药品和生物电医学的全球市场规模：按产品类型、应用、最终用户、地区、范围和预测

电子药品及生物电医学市场规模及预测

2024 年，电子药品和生物电医学市场规模为 193.8 亿美元，2024 年至 2031 年复合年增长率为 4.5%，预计到 2031 年将达到 275.6 亿美元。电疗法（生物电医学）是利用电脉衝控制体内神经迴路并治疗疾病的医疗设备。它针对特定的神经和组织，改变神经系统中的电讯号，恢復生理功能并缓解症状。电治疗药物在各医学领域有广泛的应用。它通常用于治疗慢性疼痛、神经系统疾病和糖尿病等代谢疾病。例如，植入式神经刺激器可透过阻断向大脑发出的疼痛讯号来控制慢性疼痛。

在神经病学中，深部脑部刺激（DBS）用于透过调节异常的大脑活动来治疗帕金森氏症等运动障碍。

此外，电子製药还有望用于调节心律的心臟节律和控製糖尿病管理中胰岛素分泌的生物电子植入物等应用。

电配製的未来拥有巨大的创新和扩展潜力。小型化、无线技术和生物相容性材料的进步正在提高电子製药设备的有效性和安全性。研究人员正在探索精神疾病、自体免疫疾病和胃肠道疾病等领域的新应用。

全球电子药物与生物电医学市场动态

塑造全球电子药品和生物电医药市场的关键市场动态

主要市场驱动因子

对非药物治疗的需求不断增加：

对药物副作用和依赖性的担忧促使患者和医疗保健提供者越来越倾向于非药物治疗。电疗法提供针对性的精准治疗，可以有效控制慢性疼痛、神经系统疾病和心血管疾病等疾病。根据 NIH 下属国家补充和综合健康中心 (NCCIH) 的数据，2020 年至 2023 年间，非药物疼痛管理技术的使用增加了 25%。

技术进步：

电子、材料科学和神经刺激技术的不断进步正在推动电疗药物的创新。更小的设备、更长的电池寿命和增强的无线功能正在扩大生物电子医学在不同医学专业的适用性和采用。美国国家生物医学影像与生物工程研究所 (NIBIB) 报告称，2020 年至 2023 年间，生物电子医学研究经费将增加 40%。

医疗支出增加：

全球医疗保健支出的增加，加上对具有成本效益的治疗方案的需求，正在推动电疗法的采用。这些设备有可能透过提供持久的治疗效果并最大限度地减少与慢性病相关的住院次数来降低长期医疗保健成本。根据医疗保险和医疗补助服务中心（CMS）的报告，2023年美国医疗保健支出将达到4.3兆美元，年增率为5.4%。

提高认识与接受度：

医疗保健专业人员和患者对生物电疗法益处的认识不断提高，正在推动市场接受度。积极的临床试验和患者结果增强了人们对电子药物作为可行治疗选择的信心，进一步加速了市场的成长和采用。 FDA 报告称，2020 年至 2023 年间，电疗设备的上市前批准数量增加了 35%。

主要问题

监理挑战：

医疗器材严格的监管要求和漫长的审批流程可能会对生物电子医疗领域的市场准入和产品商业化造成障碍。

有限的临床证据：

需要可靠的临床证据来证明电疗法的安全性、有效性和长期益处仍然是一个挑战。数据不足或临床结果混杂可能会阻碍医疗保健提供者和患者的采用。

成本高，价格实惠：

与电疗设备相关的高成本（包括开发、製造和维护）可能会限制市场成长和可近性，特别是在医疗保健预算有限的地区。

技术复杂性：

生物电医疗技术（包括设备植入、编程和维护）的复杂性需要对医疗保健专业人员进行专门培训，并且可能对传播和患者接受度带来挑战。

竞争格局：

电子药品市场中现有医疗器材公司与新兴新创公司之间的激烈竞争可能会导致定价压力、创新障碍和整合，从而影响市场动态和获利能力。

主要趋势

个人化医疗：

利用诊断、遗传学和数据分析方面的进步来优化治疗结果并根据患者个体情况进行个人化电子药物治疗的趋势日益明显。根据美国国立卫生研究院（NIH）预测，2020年至2023年精准医学研究经费将增加35%，2023年达18亿美元。

无线与穿戴式科技：

将无线通讯和穿戴式技术整合到电子製药中，可实现远端监控、即时数据收集和患者参与，从而提高治疗效果和患者便利性。根据美国疾病管制与预防中心 (CDC) 2023 年的报告，45% 患有慢性病的成年人使用某种可穿戴医疗技术，高于 2020 年的 32%。

扩展到新的治疗领域：

生物电子医学正在从疼痛管理和神经系统疾病等传统应用扩展到心臟病学、胃肠病学和肿瘤学等新的治疗领域，从而扩大了市场潜力。 2024年2月，Electrocore进入胃肠病学市场，并获得FDA核准用于治疗胃食道逆流（GERD）的非侵入性迷走神经刺激疗法。

目录

第1章 简介

• 市场定义
• 市场区隔
• 调查手法

第2章 摘要整理

• 主要调查结果
• 市场概要
• 市场亮点

第3章 市场概要

• 市场规模与成长潜力
• 市场趋势
• 推动市场要素
• 阻碍市场要素
• 市场机会
• 波特的五力分析

第4章 电子药品和生物电医学市场:各产品类型

• 置入式电力治疗器
• 非侵入性电力治疗设备

第5章 电子药品和生物电医学市场:各用途

• 疼痛管理
• 神经疾病
• 心臟疾病
• 消化器官疾病

第6章 电子药品和生物电医学市场:各流通管道

• 医院及诊疗所
• 门诊病人手术中心
• 研究机关

第7章 各地区分析

• 北美
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利
• 亚太地区
• 中国
• 日本
• 印度
• 澳洲
• 南美
• 巴西
• 阿根廷
• 智利
• 中东·非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯联合大公国

第8章 市场动态

• 推动市场要素
• 阻碍市场要素
• 市场机会
• COVID-19对市场的影响

第9章 竞争情形

• 主要企业
• 市场占有率分析

第10章 企业简介

• Medtronic plc
• Boston Scientific Corporation
• Abbott Laboratories, Inc.
• LivaNova PLC
• Cochlear Ltd.
• Axonics Modulation Technologies, Inc.
• Neuronetics, Inc.
• Second Sight Medical Products, Inc.
• NeuroPace, Inc.
• BIOTRONIK SE & Co. KG

第11章 市场展望和机会

• 新兴技术
• 今后的市场趋势
• 投资机会

第12章 附录

• 简称清单
• 出处和参考文献

Electroceuticals Bioelectric Medicine Market Size And Forecast

Electroceuticals Bioelectric Medicine Market size was valued at USD 19.38 Billion in 2024 and is projected to reach USD 27.56 Billion by 2031, growing at a CAGR of 4.5% from 2024 to 2031. Electroceuticals, or bioelectric medicine, are medical devices that use electrical impulses to modulate neural circuits in the body to treat diseases. They target specific nerves or tissues, restoring physiological function or alleviating symptoms by altering electrical signals in the nervous system. Electroceuticals have diverse applications across various medical fields. They are commonly used in the treatment of chronic pain, neurological disorders, and metabolic conditions such as diabetes. For example, implantable neurostimulators can be used to manage chronic pain by blocking pain signals to the brain.

In neurology, deep brain stimulation (DBS) is employed to treat movement disorders like Parkinson's disease by modulating abnormal brain activity.

Additionally, electroceuticals show promise in applications such as cardiac pacing to regulate heart rhythms and bioelectronic implants to control insulin release in diabetes management.

The future of electroceuticals holds significant potential for innovation and expansion. Advancements in miniaturization, wireless technology, and biocompatible materials are enhancing the effectiveness and safety of electroceutical devices. Researchers are exploring new applications in areas such as mental health disorders, autoimmune diseases, and gastrointestinal disorders.

Global Electroceuticals Bioelectric Medicine Market Dynamics

The key market dynamics that are shaping the global electroceuticals bioelectric medicine market include:

Key Market Drivers

Increasing Demand for Non-pharmacological Therapies:

There is a growing preference among patients and healthcare providers for non-pharmacological treatments due to concerns over drug side effects and dependency. Electroceuticals offer targeted, precise therapies that can effectively manage conditions such as chronic pain, neurological disorders, and cardiovascular diseases. According to the National Center for Complementary and Integrative Health (NCCIH), a division of the NIH, the use of non-pharmacological pain management techniques increased by 25% between 2020 and 2023.

Technological Advancements:

Continuous advancements in electronics, materials science, and neurostimulation techniques are driving innovation in electroceuticals. Miniaturization of devices, improved battery life, and enhanced wireless capabilities are expanding the applicability and adoption of bioelectric medicine across diverse medical specialties. The National Institute of Biomedical Imaging and Bioengineering (NIBIB) reported a 40% increase in funding for bioelectronic medicine research between 2020 and 2023.

Rising Healthcare Expenditure:

Increasing healthcare expenditure globally, coupled with the need for cost-effective treatment options, is boosting the adoption of electroceuticals. These devices can potentially reduce long-term healthcare costs by offering long-lasting therapeutic benefits and minimizing hospitalizations related to chronic conditions. The Centers for Medicare & Medicaid Services (CMS) reported that U.S. healthcare spending reached $4.3 trillion in 2023, with a 5.4% annual growth rate.

Growing Awareness and Acceptance:

Rising awareness among healthcare professionals and patients about the benefits of bioelectric therapies is driving market acceptance. Clinical studies and successful patient outcomes are increasing confidence in electroceuticals as viable treatment options, further accelerating market growth and adoption. The FDA reported a 35% increase in premarket approvals for electroceutical devices between 2020 and 2023.

Key Challenges:

Regulatory Challenges:

Stringent regulatory requirements and lengthy approval processes for medical devices can pose barriers to market entry and product commercialization in the bioelectric medicine sector.

Limited Clinical Evidence:

The need for robust clinical evidence to demonstrate safety, efficacy, and long-term benefits of electroceutical therapies remains a challenge. Insufficient data or mixed clinical outcomes may hinder adoption by healthcare providers and patients.

High Costs and Affordability:

The high costs associated with electroceutical devices, including development, manufacturing, and maintenance, can limit market growth and accessibility, particularly in regions with constrained healthcare budgets.

Technological Complexity:

The complexity of bioelectric medicine technologies, including device implantation, programming, and maintenance, requires specialized training for healthcare professionals and may pose challenges in widespread adoption and patient acceptance.

Competitive Landscape:

Intense competition among established medical device companies and emerging startups in the electroceuticals market can lead to pricing pressures, innovation barriers, and consolidation, impacting market dynamics and profitability.

Key Trends

Personalized Medicine:

There is a growing trend towards personalized electroceutical therapies tailored to individual patient profiles, leveraging advancements in diagnostics, genetics, and data analytics to optimize treatment outcomes. According to the National Institutes of Health (NIH), funding for precision medicine research increased by 35% between 2020 and 2023, reaching $1.8 billion in 2023.

Wireless and Wearable Technologies:

Integration of wireless communication and wearable technologies in electroceuticals allows for remote monitoring, real-time data collection, and patient engagement, enhancing treatment efficacy and patient convenience. A 2023 report from the Centers for Disease Control and Prevention (CDC) found that 45% of adults with chronic conditions used some form of wearable health technology, up from 32% in 2020.

Expansion into New Therapeutic Areas:

Bioelectric medicine is expanding beyond traditional applications like pain management and neurological disorders into new therapeutic areas such as cardiology, gastroenterology, and oncology, broadening its market potential. In February 2024, electroCore received FDA clearance for its non-invasive vagus nerve stimulation therapy to treat gastroesophageal reflux disease (GERD), marking its entry into the gastroenterology market.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Electroceuticals Bioelectric Medicine Market Regional Analysis

Here is a more detailed regional analysis of the global electroceuticals bioelectric medicine market:

North America

North America dominating the electroceuticals market due to several key factors. The region benefits from a robust healthcare infrastructure that facilitates adoption of advanced medical technologies. The American Hospital Association's 2023 annual survey revealed that 68% of U.S. hospitals had implemented at least one form of electroceutical therapy, up from 52% in 2020.

Technological advancements in neurostimulation and cardiac therapies are particularly prominent, supported by substantial healthcare expenditure and a proactive regulatory environment that fosters innovation. The National Institutes of Health (NIH) allocated USD 985 Million to neurotechnology research in fiscal year 2023, a 15% increase from 2021.

Strong research and development activities further enhance North America's position, driving continuous advancement and application of bioelectric medicine in clinical settings. The National Science Foundation reported that private sector R&D investment in medical equipment and supplies, including electroceuticals, reached USD 21.8 Billion in 2023, a 9.5% increase from 2021.

Asia Pacific

Asia Pacific is indeed emerging as a rapidly growing market for electroceuticals. The region's growth is fueled by increasing investments in healthcare infrastructure and technology, driven by countries such as China, Japan, and India. According to the World Health Organization (WHO), healthcare spending in the Asia Pacific region increased by an average of 7.2% annually between 2020 and 2023.

These nations are experiencing a rising prevalence of chronic diseases and expanding medical tourism, which further boosts demand for advanced medical treatments, including neuromodulation and cardiac devices. India's Ministry of Tourism reported that medical visa arrivals increased by 32% in 2023 compared to 2021, with neurology and cardiology being among the top specialties sought by international patients.

This trend underscores Asia Pacific's evolving role as a key player in the global electroceuticals market, supported by efforts to enhance healthcare access and technological capabilities. The China National Medical Products Administration (NMPA) approved 28 new electroceutical devices in 2023, compared to 18 in 2021, indicating accelerated innovation and regulatory support.

Global Electroceuticals Bioelectric Medicine Market: Segmentation Analysis

The Global Electroceuticals Bioelectric Medicine Market is Segmented on the basis of Product Type, Application, End-User, and Geography.

Electroceuticals Bioelectric Medicine Market, By Application

• Pain Management
• Neurological Disorders
• Cardiac Disorders
• Gastrointestinal Disorders

Based on Application, the Global Electroceuticals Bioelectric Medicine Market is bifurcated into Pain Management, Neurological Disorders, Cardiac Disorders, and Gastrointestinal Disorders. In the electroceuticals bioelectric medicine market, neurological disorders currently dominate as the leading application segment. This dominance is driven by the widespread adoption of neurostimulation therapies for conditions such as Parkinson's disease, epilepsy, and chronic pain syndromes. Neurological disorders benefit significantly from the precise targeting and modulation of neural circuits offered by bioelectric medicine, enhancing patient outcomes and quality of life. The Cardiac Disorders segment is rapidly growing, fueled by advancements in cardiac neuromodulation techniques and devices aimed at managing arrhythmias, heart failure, and other cardiovascular conditions.

Electroceuticals Bioelectric Medicine Market, By Product Type

• Implantable Electroceutical Devices
• Non-invasive Electroceutical Devices

Based on Product Type, the Global Electroceuticals Bioelectric Medicine Market is bifurcated into Implantable Electroceutical Devices and Non-invasive Electroceutical Devices. In the market, implantable electroceutical devices currently dominate as the leading product type segment. These devices, such as neurostimulators and implantable cardiac devices, offer targeted therapy directly at the site of action within the body, providing long-term management of chronic conditions like Parkinson's disease and cardiac arrhythmias. The precision and effectiveness of implantable devices contribute to their widespread adoption and market dominance. The Non-invasive Electroceutical Devices segment is rapidly growing, driven by advancements in technologies like transcutaneous electrical nerve stimulation (TENS) and external neuromodulation devices.

Electroceuticals Bioelectric Medicine Market, By End-User

• Hospitals and Clinics
• Ambulatory Surgical Centers
• Research Institutes

Based on End-User, the Global Electroceuticals Bioelectric Medicine Market is bifurcated into Hospitals and Clinics, Ambulatory Surgical Centers, Research Institutes. In the electroceuticals bioelectric medicine market, hospitals and clinics is expected to dominate the leading end-user segment. Hospitals and clinics are primary settings for the diagnosis, treatment, and management of chronic conditions that benefit from bioelectric therapies, such as neurological disorders and cardiac diseases. These healthcare facilities have the infrastructure and expertise to support the use of electroceutical devices, driving their widespread adoption and market dominance. The Ambulatory Surgical Centers segment is rapidly growing, fueled by the increasing trend towards outpatient procedures and minimally invasive treatments using electroceutical devices.

Electroceuticals Bioelectric Medicine Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global Electroceuticals Bioelectric Medicine Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. In the market, North America is anticipated to lead geographical segment. This region benefits from a mature healthcare infrastructure, significant investments in research and development, and a proactive regulatory environment that supports the adoption of bioelectric medicine. North America's dominance is further bolstered by high healthcare expenditure and robust market penetration of advanced neurostimulation and cardiac devices. Asia Pacific is rapidly growing in the electroceuticals market, driven by increasing healthcare investments, rising prevalence of chronic diseases, and expanding adoption of advanced medical technologies.

Key Players

• The "Global Electroceuticals Bioelectric Medicine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Inc., LivaNova PLC, Cochlear Ltd., Neuronetics, Inc., Second Sight Medical Products, Inc., NeuroPace, Inc., and BIOTRONIK SE & Co. KG.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Electroceuticals Bioelectric Medicine Market Key Developments

• In March 2024, Medtronic announced the FDA approval of its next-generation closed-loop deep brain stimulation system for Parkinson's disease. The system features adaptive stimulation based on real-time brain signals, marking a significant advancement in personalized neuromodulation therapy.
• In January 2024, Boston Scientific launched a new spinal cord stimulation platform with advanced pain targeting algorithms. The system incorporates AI-driven technology to optimize stimulation parameters based on individual patient responses, enhancing treatment efficacy for chronic pain conditions.
• In November 2023, Abbott Laboratories introduced a wireless neuromodulation system for chronic pain management. The device allows patients to control and monitor their therapy via a smartphone app, improving patient engagement and treatment adherence.
• In September 2023, Nevro Corp. received FDA approval for an expanded indication of its high-frequency spinal cord stimulation therapy to include treatment of painful diabetic neuropathy. This approval opens up a significant new market for the company's electroceutical technology.
• In July 2023, electroCore secured FDA clearance for its non-invasive vagus nerve stimulation therapy to treat gastroesophageal reflux disease (GERD). This marks the company's entry into the gastroenterology market, broadening the application of bioelectric medicine beyond its traditional domains.
• In April 2023, SetPoint Medical initiated a Phase II clinical trial for its bioelectronic therapy in treating inflammatory bowel disease. This development represents a significant step in expanding the application of electroceuticals to autoimmune disorders beyond rheumatoid arthritis.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Electroceuticals Bioelectric Medicine Market, By Product Type

• Implantable Electroceutical Devices
• Non-invasive Electroceutical Devices

5. Electroceuticals Bioelectric Medicine Market, By Application

• Pain Management
• Neurological Disorders
• Cardiac Disorders
• Gastrointestinal Disorders

6. Electroceuticals Bioelectric Medicine Market, By Distribution Channel

• Hospitals and Clinics
• Ambulatory Surgical Centers
• Research Institutes

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Medtronic plc
• Boston Scientific Corporation
• Abbott Laboratories, Inc.
• LivaNova PLC
• Cochlear Ltd.
• Axonics Modulation Technologies, Inc.
• Neuronetics, Inc.
• Second Sight Medical Products, Inc.
• NeuroPace, Inc.
• BIOTRONIK SE & Co. KG

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References